Invida Group Extends Contract With Actelion For Tracleer

Initially, Actelion had signed contract with Invida in 2005 and has extended it to market Tracleer in Thailand, Malaysia, Philippines, Vietnam and Hong Kong

Invida is expected to continue to leverage its experience in regulatory and medical affairs, specialised marketing, and its well-established network of key opinion leaders throughout the region. Th

Invida Group said that this partnership will allow it to work with a biotech firm and leverage its capabilities to commercialise an orphan drug that has proven ability to positively impact disease progression, as well as reduce severity and symptoms in patients with PAH.

Bill Fairey, vice president of Australia-Asia Pacific Region at Actelion, said: “We are pleased to announce the continuation of our partnership with Invida, as their demonstrated expertise in commercializing the Tracleer brand has helped our sales grow in an increasingly competitive environment. Invida has increased our presence in Asia and has given Actelion an edge in the global markets and a crucial foothold as we look forward to commercializing more products from our pipeline.”

John Graham, CEO of Invida, said: “We are thrilled that we have extended our partnership with Actelion to continue our practice of furthering scientific breakthroughs by working with the world’s market-leading biotechnology companies. Invida is focused on fostering innovation and bringing cutting-edge pharmaceutical products to the Asia-Pacific region, and Actelion continues to provide us with a unique and exciting opportunity to do so.”